Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Auger electron emitters such as (125)I have a high linear energy transfer and short range of emission (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. We used a highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver (125)I to prostate cancer cells. METHODS: The PSMA-targeting Auger emitter 2-[3-[1-carboxy-5-(4-(125)I-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ((125)I-DCIBzL) was synthesized. DNA damage (via phosphorylated H2A histone family member X staining) and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human prostate cancer cells after treatment with (125)I-DCIBzL. Subcellular drug distribution was assessed with confocal microscopy using a related fluorescent PSMA-targeting compound YC-36. In vivo antitumor efficacy was tested in nude mice bearing PSMA+ PC3 PIP or PSMA- PC3 flu flank xenografts. Animals were administered (intravenously) 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabeled DCIBzL, or saline. RESULTS: After treatment with (125)I-DCIBzL, PSMA+ PC3 PIP cells exhibited increased DNA damage and decreased clonogenic survival when compared with PSMA- PC3 flu cells. Confocal microscopy of YC-36 showed drug distribution in the perinuclear area and plasma membrane. Animals bearing PSMA+ PC3 PIP tumors had significant tumor growth delay after treatment with (125)I-DCIBzL, with only 1 mouse reaching 5 times the initial tumor volume by 60 d after treatment, compared with a median time to 5 times volume of less than 15 d for PSMA- PC3 flu tumors and all other treatment groups (P = 0.002 by log-rank test). CONCLUSION: PSMA-targeted radiopharmaceutical therapy with the Auger emitter (125)I-DCIBzL yielded highly specific antitumor efficacy in vivo, suggesting promise for treatment of prostate cancer micrometastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
Hobbs, R. F., Song, H., Huso, D. L., H Sundel, M., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/13/4403 · Cited by 61 · cited 1×
“That highlights the importance of rigorous macro- to microlevel dosimetry for targeted RPTs, especially those with short ranges such as Auger and a emitters (26,37).”
BackgroundSelf-citation
Cited by
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Self-citationKratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
“After binding at the tumor cell surface, PSMA ligands are internalized (5), which is considered particularly beneficial for short-range Auger (6) and a-particle radiation (7) and is especially important for radionuclides that decay into unstable daughter nuclides.”
BackgroundAdvancements in the use of Auger electrons in science and medicine during the period 2015–2019
Howell, R. W. (2023) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1831706 · Cited by 274
Banerjee, S. R., Foss, C. A., Horhota, A., Pullambhatla, M., McDonnell, K., Zale, S., & Pomper, M. G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01485 · Cited by 54
Self-citationZukotynski, K., Jadvar, H., Capala, J., & Fahey, F. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s31804 · Cited by 51
Metadata
- Authors
- Kiess, A. P., Minn, I., Chen, Y., Hobbs, R., Sgouros, G., Mease, R. C., Pullambhatla, M., Shen, C. J., Foss, C. A., & Pomper, M. G.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2015-07-16
- Volume
- 56
- Issue
- 9
- Pages
- 1401-1407
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2137571973
- Cited by
- 111
- References
- 2
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. https://app.cochat.ai/papers/10.2967/jnumed.115.155929
- The paper
- Kiess, A. P., Minn, I., Chen, Y., Hobbs, R., Sgouros, G., Mease, R. C., Pullambhatla, M., Shen, C. J., Foss, C. A., & Pomper, M. G. (2015). Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.115.155929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.